Fecal Microbiota Transplantation for Irritable Bowel Syndrome

Launched by GUANGZHOU FIRST PEOPLE'S HOSPITAL · Aug 1, 2018

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called fecal microbiota transplantation (FMT) to see if it can help people with Irritable Bowel Syndrome (IBS). FMT involves taking healthy bacteria from a donor's stool and placing it into the gut of someone with IBS. The goal is to restore the balance of good bacteria in the intestines, which may improve symptoms and overall gut health. While FMT has shown success in treating other conditions, this study aims to find out if it is effective and safe for IBS patients.

To participate in the study, individuals must be between 18 and 75 years old and diagnosed with IBS based on specific criteria. Those who are pregnant, have severe health issues like liver or kidney failure, or have other intestinal diseases will not be eligible. Participants can expect to undergo a procedure where the healthy bacteria are introduced into their gut, and they will be monitored for any changes in their symptoms. This study is currently recruiting, and it's a chance to explore a new treatment option for managing IBS.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• To be considered eligible for enrolment into the study, subjects must:
• • Be able to give written informed consent.
• • Males and females aged \>18 and \<75
• • Have IBS as defined by the Rome IV criteria
• Exclusion Criteria:
• Subjects will be excluded from the study if they meet any of the below criteria:
• • pregnant or having a follow-up of less than 6 months;
• • unable to give informed consent;
• • suffering from other severe disease ,including liver and kidney failure, cancers, intestinal diseases, inflammatory bowel disease, C difficile infection;
• • unable to undergo endoscopy.